Bimzelx and Siliq Comparison

Bimzelx®(bimekizumab-bkzx)	Siliq®(brodalumab)
Prescription Only Bimzelx (bimekizumab) is a medication classified as an interleukin inhibitor, prescribed for the treatment of certain types of plaque psoriasis in adults. It functions by reducing...	Prescription Only Siliq is used to treat moderate to severe plaque psoriasis in adults. Siliq is usually given after other treatments have failed. Siliq is FDA approved for the following...
Administration
Subcutaneous. Learn more.	Subcutaneous Injection. Learn more.
Dosing
The recommended dosage of BIMZELX is 320 mg (given as 2 subcutaneous injections of 160 mg each) at Weeks 0, 4, 8, 12, and 16, then every 8 weeks thereafter. For patients weighing ≥ 120 kg, consider a dosage of 320 mg every 4 weeks after Week 16.. Learn more.	Administer 210 mg of SILIQ by subcutaneous injection at Weeks 0, 1, and 2 followed by 210 mg every 2 weeks.. Learn more.
Latin Shorthand
The recommended dosage of BIMZELX is 320 mg (given as 2 subcutaneous injections of 160 mg each) at Weeks 0, 4, 8, 12, and 16, then every 8 weeks thereafter. For patients weighing ≥ 120 kg, consider a dosage of 320 mg every 4 weeks after Week 16.. Learn more.	210mg SC Wks 0,1,2, then 210mg q2w.. Learn more.
Out-Of-Pocket Costs With Copay Card
$5 or $15. Learn more.	$25. Learn more.
Annual Cap
Learn more.	$20,000. Learn more.
Assistance Expiration
2 years. Learn more.	12 months. Learn more.
Generics
No lower-cost generic available	No lower-cost generic available
Adverse Reactions
The following adverse reactions have been observed with BIMZELX and are discussed in greater detail in other sections of the labeling: Suicidal Ideation and Behavior [see Warnings and Precautions (5.1)] Infections [see Warnings and Precautions (5.2)] Liver Biochemical Abnormalities [see Warnings and Precautions (5.4)] Inflammatory Bowel Disease [see Warnings and Precautions (5.5)]. Learn more.	Most common adverse reactions (incidence ≥1%) were arthralgia, headache, fatigue, diarrhea, oropharyngeal pain, nausea, myalgia, injection site reactions, influenza, neutropenia, and tinea infections. . Learn more.
Mechanism of Actions (MoA)
Interleukin 17A and Interleukin 17F Antagonist. Learn more.	Interleukin 17A Antagonist . Learn more.
Special Populations
	What is the risk of using SILIQ during pregnancy? There are no human data on SILIQ use in pregnant women to inform a drug-associated risk. SILIQ may be transmitted from the mother to the developing fetus. In a combined embryofetal development and pre- and postnatal development study, no adverse developmental effects were observed in infants born to pregnant monkeys after subcutaneous administration of brodalumab during organogenesis through parturition at doses up to 26 times the maximum recommended human dose (MRHD). However, the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. What is the risk of using SILIQ during lactation? There are no data on the presence of brodalumab in human milk, the effects on the breastfed infant, or the effects on milk production. Brodalumab was detected in the milk of lactating cynomolgus monkeys. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for SILIQ and any potential adverse effects on the breastfed infant from SILIQ or from the underlying maternal condition. Is SILIQ safe and effective for pediatric patients? The safety and effectiveness of SILIQ have not been evaluated in pediatric patients. Is SILIQ safe and effective for geriatric patients? Of the 3066 plaque psoriasis subjects initially randomized to SILIQ in clinical trials, 192 (6%) were ≥ 65 years old and no subjects were ≥ 75 years old. Although no differences in safety or efficacy were observed between older and younger subjects, the number of subjects aged 65 years and older was not sufficient to determine whether they responded differently from younger subjects.

Bimzelx®(bimekizumab-bkzx)

Siliq®(brodalumab)

Prescription Only

Bimzelx (bimekizumab) is a medication classified as an interleukin inhibitor, prescribed for the treatment of certain types of plaque psoriasis in adults. It functions by reducing...

Prescription Only

Siliq is used to treat moderate to severe plaque psoriasis in adults. Siliq is usually given after other treatments have failed. Siliq is FDA approved for the following...

Dosage & Administration

Administration

Subcutaneous. Learn more.

Subcutaneous Injection. Learn more.

Dosing

The recommended dosage of BIMZELX is 320 mg (given as 2 subcutaneous injections of 160 mg each) at Weeks 0, 4, 8, 12, and 16, then every 8 weeks thereafter. For patients weighing ≥ 120 kg, consider a dosage of 320 mg every 4 weeks after Week 16.. Learn more.

Administer 210 mg of SILIQ by subcutaneous injection at Weeks 0, 1, and 2 followed by 210 mg every 2 weeks.. Learn more.

Latin Shorthand

210mg SC Wks 0,1,2, then 210mg q2w.. Learn more.

Financial Assistance

Out-Of-Pocket Costs With Copay Card

$5 or $15. Learn more.

$25. Learn more.

Annual Cap

Learn more.

$20,000. Learn more.

Assistance Expiration

2 years. Learn more.

12 months. Learn more.

Generics

No lower-cost generic available

Physician Advisory

Adverse Reactions

The following adverse reactions have been observed with BIMZELX and are discussed in greater detail in other sections of the labeling: Suicidal Ideation and Behavior [see Warnings and Precautions (5.1)] Infections [see Warnings and Precautions (5.2)] Liver Biochemical Abnormalities [see Warnings and Precautions (5.4)] Inflammatory Bowel Disease [see Warnings and Precautions (5.5)]. Learn more.

Most common adverse reactions (incidence ≥1%) were arthralgia, headache, fatigue, diarrhea, oropharyngeal pain, nausea, myalgia, injection site reactions, influenza, neutropenia, and tinea infections. . Learn more.

Mechanism of Actions (MoA)

Interleukin 17A and Interleukin 17F Antagonist. Learn more.

Interleukin 17A Antagonist . Learn more.

Special Populations

What is the risk of using SILIQ during pregnancy?

There are no human data on SILIQ use in pregnant women to inform a drug-associated risk. SILIQ may be transmitted from the mother to the developing fetus. In a combined embryofetal development and pre- and postnatal development study, no adverse developmental effects were observed in infants born to pregnant monkeys after subcutaneous administration of brodalumab during organogenesis through parturition at doses up to 26 times the maximum recommended human dose (MRHD). However, the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

What is the risk of using SILIQ during lactation?

There are no data on the presence of brodalumab in human milk, the effects on the breastfed infant, or the effects on milk production. Brodalumab was detected in the milk of lactating cynomolgus monkeys. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for SILIQ and any potential adverse effects on the breastfed infant from SILIQ or from the underlying maternal condition.

Is SILIQ safe and effective for pediatric patients?

The safety and effectiveness of SILIQ have not been evaluated in pediatric patients.

Is SILIQ safe and effective for geriatric patients?

Of the 3066 plaque psoriasis subjects initially randomized to SILIQ in clinical trials, 192 (6%) were ≥ 65 years old and no subjects were ≥ 75 years old. Although no differences in safety or efficacy were observed between older and younger subjects, the number of subjects aged 65 years and older was not sufficient to determine whether they responded differently from younger subjects.

Bimzelx® Alternatives